



PRESS RELEASE

BSE: 506690

NSE: UNICHEMLAB

Reuters: UNLB.BO

Bloomberg: UN@IN

Mumbai, November 10, 2009

Unichem Laboratories received approval for its bulk drug [API] facility situated at Pithampur from US FDA

Unichem Laboratories Limited is pleased to announce that it has received approval for its Bulk drug [API] facility situated at Pithampur from US FDA. With this approval, both bulk drug facilities situated at Roha, Maharashtra and Pithampur, Madhya Pradesh are duly approved by US FDA. The Company's formulation facilities at Goa and Ghaziabad are already approved by US FDA.

About Unichem Laboratories Limited.

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, orthopedics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms. More information about the company can be found at www.unichemindia.com.

Contacts:

Mr. K Subharaman

Tel: +912266888404

Cell: +919833031121

e-Mail: subharamank@unichemindia.com

Mr. Rakesh Parikh

Tel: +912266888414

Cell: +919892925555

e-Mail: rparikh@unichemindia.com

Mr. M Gundu Rao

Tel: +912266888380

Cell: +919820228944

e-Mail: gundurao@unichemindia.com

This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

-o0o-